Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Ang, Celina; Balcar, Lorenz; Bettinger, Dominik; Cammarota, Antonella; Cheon, Jaekyung; Chon, Hong Jae; Cortellini, Alessio; D'Alessio, Antonio; Fulgenzi, Claudia Angela Maria; Gaillard, Vincent E; Galle, Peter R; Huang, Yi-Hsiang; Kudo, Masatoshi; Marron, Thomas U; Masi, Gianluca; Napolitano, Andrea; Naqash, Abdul Rafeh; Nishida, Naoshi; Personeni, Nicola; Phen, Samuel; Pinato, David James; Pinter, Matthias; Pressiani, Tiziana; Rimassa, Lorenza; Saeed, Anwaar; Salani, Francesca; Scheiner, Bernhard; Schönlein, Martin; Schulze, Kornelius; Sharma, Rohini; Singal, Amit G; Vivaldi, Caterina; Vogel, Arndt; von Felden, Johann; Wege, Henning; Wietharn, Brooke; Wu, Linda

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Abstract

IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC)

Similar works

Full text

Open in the Core reader

Download PDF

Available Versions

Crossref

info:doi/10.1016%2Fj.ejca.2022...

Last time updated on 03/03/2024

Archivio della Ricerca - Università di Pisa

oai:arpi.unipi.it:11568/116021...

Last time updated on 11/02/2024